Welcome to the Technofunda Investing community. Thank you for being Life Long Learner...!!!
Share this newsletter Via: LinkedIn, WhatsApp, Twitterβ
You can view all previous newsletters hereβ
π Market Kya Lagta Hai
Nifty 50 π»-2.19%
Midcap 150 π»-4.98%
Smallcap 250 π»-5.71%
|
Sectors in Focus
Major Corporate Developments This Week
- RVNL: Company emerged lowest bidder for a South Western Railway project worth Rs 156.35 crore.
- Lupin: US FDA issues Establishment Inspection Report (EIR) for companyβs manufacturing facility in Somerset, New Jersey
- JTL Industries: Company Enters MOU with RCI for 200 Mt/Month Copper And Brass Alloys.
- MOIL: Co says prices of all ferro grades of manganese ore with manganese content of Mn-44% and above have been increased by 10%.
- AstraZeneca Pharma India: Co has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Govt of India to import for sale and distribution of Durvalumab solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi) for an additional indication.
- Solar Industries India: Co unit received defence export orders worth βΉ2,160 crore.
- Zen Technologies: Co secures patent for automated hard kill firearm mounting system.
- Biocon Limited: Co launches its glucagon-like peptide-1 (GLP-1), Liraglutide, in the United Kingdom.
- Transrail Lighting: Co wins new orders of βΉ2,752 crore, strengthening its position in the transmission & distribution sector.
- Tata Power: TP Solar Limited, Tata Powerβs solar manufacturing arm, wins βΉ632 crore contract from SECI to supply 292.5 MWP DCR solar modules.
- Orient Tech: Co announces its collaboration with Amazon Web Services (AWS) India to offer advanced GPU and AI services.
- Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA launches epinephrine injection USP, 10 mg/10 ml, multiple-dose vial. This injection has achieved annual sales of approximately USD 42.7 million.
- Jupiter Wagons: Jupiter Tatravagonka Railwheel Factory secures βΉ255 crore order from Braithwaite & Co. Co says new Odisha facility to boost annual production to 1,00,000 wheel sets, reducing reliance on imports.
- Mastek: Co secures multi-year, multi-million dollar contracts from the UK public service department. Co secures contracts worth $85 million over 2 years.
- Caplin Point Laboratories: Co unit Caplin Steriles gets USFDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic (eye drops). Co unit gets USFDA nod for glaucoma drugs. According to IQVIAβ’ (IMS Health), Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution had US sales of approximately $242 million for the 12-month period ending December 2024.
- KPI Green Energy: KP Group signs MoU with Madhya Pradesh Govt for 1.8 GW renewable projects.
- Marksans Pharma: Co subsidiary in UK, Relonchem Limited, receives marketing authorization for the product Ibuprofen and Paracetamol 200 mg/500 mg film-coated tablets.
- Jyoti Structures: Co gets βΉ3.89 billion order from Adani Energy.
- Gensol Engineering: Co unlocks value with βΉ350 crore strategic deal for Scorpius Trackers' US subsidiary.
- Healthcare Global Enterprises: KKR acquires controlling stake in Co for USD 400 million. KKR is expected to hold an equity stake of between 54-77%. KKR to be the largest and controlling shareholder.
TechnoFunda Investing Quote from Legends -
Jean-Marie Eveillard's quote emphasizes the critical role of risk management in investing. While making high returns is appealing, long-term success is ultimately determined by how well an investor protects their capital. Significant losses can be difficult to recover from due to the mathematics of compoundingβlosing 50% of a portfolio requires a 100% gain just to break even. By focusing on preserving capital, avoiding reckless speculation, and managing downside risk, investors can ensure they stay in the game long enough to capitalize on opportunities while minimizing irreversible damage. This principle aligns with the wisdom of legendary investors who prioritize avoiding large drawdowns over chasing short-term gains.
π Book I'm Reading This Week
What I Learned Losing a Million Dollars by Jim Paul and Brendan Moynihan is a compelling exploration of the psychological pitfalls that lead investors to catastrophic losses. The book chronicles Jim Paul's personal journey from rapid success to devastating failure in the financial markets, highlighting the emotional biases and behavioural mistakes that cloud rational decision-making. Unlike traditional investing books that focus on winning strategies, this one emphasizes how avoiding losses and understanding risk management are crucial to long-term success. Through a blend of personal anecdotes and market insights, the book offers a valuable lesson: the key to investing isnβt just knowing how to win, but mastering the art of not losing.
|
TechnoFunda 101 - Power Capsules
Learn technical as well as fundamental concept in a simple way
Return on Invested Capital (ROIC) β The Ultimate Efficiency Metric
ROIC is one of the most powerful indicators of a companyβs ability to generate sustainable returns on the capital it invests. Unlike other profitability ratios, ROIC factors in both equity and debt, making it a comprehensive measure of capital efficiency.
π What is ROIC?
Return on Invested Capital (ROIC) measures how effectively a company reinvests its capital to generate profits.
π Formula:
ROIC = [Net Operating Profit After Tax (NOPAT)\Invested Capital]Γ100
Where:
- NOPAT (Net Operating Profit After Tax) = Operating Profit Γ (1 - Tax Rate)
- Invested Capital = Total Debt + Shareholdersβ Equity - Cash & Equivalents
Why exclude cash? Because cash sitting idle isnβt truly invested in operations.
β
π‘ Why is ROIC Important?
πΉ Capital Allocation: Helps investors see if a company is efficiently using capital to create shareholder value.
πΉ Comparing Businesses: Higher ROIC means better returns on investment compared to peers.
πΉ Long-Term Performance Indicator: Companies with consistently high ROIC tend to compound wealth faster over time.
β
π ROIC vs. Cost of Capital (WACC)
- If ROIC > Weighted Average Cost of Capital (WACC) β The company is creating value.
- If ROIC < WACC β The company is destroying value.
π‘ Example:
If a company earns 15% ROIC but its cost of capital (WACC) is 10%, it is creating 5% excess returnsβa sign of efficient capital deployment.
β
π How to Use ROIC in Stock Analysis?
1οΈβ£ Identify Competitive Advantages
A consistently high ROIC signals a strong moat, such as:
β
Brand Power (e.g., Apple, NestlΓ©)
β
Pricing Power (e.g., Asian Paints, Pidilite)
β
Network Effects (e.g., Google, Visa)
2οΈβ£ Compare Across Sectors
- Asset-Light Businesses (e.g., IT, FMCG): High ROIC (20%+), as they need minimal capital to grow.
- Capital-Intensive Businesses (e.g., Manufacturing, Infrastructure): Lower ROIC but should still exceed WACC.
3οΈβ£ Spot Cyclical Traps
Companies in cyclical industries (e.g., metals, oil) may show temporary spikes in ROIC due to commodity cycles. Sustainable ROIC matters more than short-term fluctuations.
β
π Key Takeaways
β
ROIC measures true capital efficiency, considering both debt & equity.
β
Always compare ROIC with WACC to check value creation.
β
High ROIC is a hallmark of companies with strong moats.
β
Use sector benchmarks to interpret ROIC correctly.
Would you like a visual breakdown of ROIC components? ππ
ποΈ My Weekly Podcast For You
Keep Compounding...
|
|
Vivek Mashrani, CFA
Founder, TechnoFunda Investing
|
|
|
You Can Share This Newsletter...!!!
|
|
|
Follow all my content on my social media handles below
|
Disclaimer:
- The content provided on this page by the publisher is not guaranteed to be accurate or comprehensive. All opinions and statements expressed herein are solely those of the author.
- The information found on this newsletter should not be interpreted as investment advice, nor does it express any viewpoint on the future trading prices of any company's securities. The opinions and information shared here should not be taken as specific guidance for making investment decisions.
- The content, including opinions and expressions, present on this newsletter, is not a direct or indirect offer or solicitation to buy or sell securities or financial instruments mentioned. The securities quoted are for illustration only and are not recommendatory.
- Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
- By accessing the site or affiliated social media accounts, you signify your agreement to this disclaimer and the terms of use.
- Neither the publisher nor its affiliates assume liability for any direct or consequential losses arising directly or indirectly from the use of the information provided in this content.